Synergy Pharmaceuticals to Present at the 8th Annual BioPartnering North America (BPN) Conference in Vancouver, BC, Canada

BioPartnering North America 2010

NEW YORK--Synergy Pharmaceuticals, Inc. (OTC BB: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that Dr. Gary S. Jacob, the Company's President & Chief Executive Officer, will present at the 8th Annual BioPartnering North America (BPN) Conference which is being held on January 24th - 26th, 2010 at the Westin Bayshore Resort in Vancouver, BC. The Company is scheduled to present on Monday, January 25th at 1:30 PM PST in the Coquitlam Room (Stream 2).

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug SP-304 began clinical development in June 2008 for gastro-intestinal disorders. SP-304 recently finished a Phase I clinical trial in volunteers and the Company plans to initiate a Phase IIa clinical trial of SP-304 in chronic constipation patients in the first quarter of 2010. SP-304 is a synthetic analog of the human gastrointestinal hormone uroguanylin, and acts by activating the guanylate cyclase C (GC-C) receptor on epithelial cells of the GI tract. More information is available at http://www.synergypharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Synergy believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Synergy Pharmaceuticals Annual Report on Form 10-K for the year ended December 31, 2008, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in
early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Synergy will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing.

Synergy Pharmaceuticals, Inc.
Gary S. Jacob, Ph.D., +1-212-297-0020

or
Investors:
Kilmer Lucas Inc.
Stephen Kilmer, +1-905-690-2400 ext. 21
President and CEO President